Deficiency in asparagine synthetase expression in rectal cancers receiving concurrent chemoradiotherapy: Negative prognostic impact and therapeutic relevance

Tumor Biology

Volumn 35, Issue 7, 2014, Pages 6823-6830

  Lin, Ching Yih ^a,b   Sheu, Ming Jen ^a   Li, Chien Feng ^a,b,c,d   Lee, Sung Wei ^a   Lin, Li Ching ^a   Wang, Yi Fong ^b   Chen, Shang Hung ^a,c  

^a CHI MEI MEDICAL CENTER   (Taiwan)

^b SOUTHERN TAIWAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

^c NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^d KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

ASNS; CCRT; Rectal Cancer

Indexed keywords

ASPARTATE AMMONIA LIGASE; FLUOROURACIL; MESSENGER RNA; PHENYLALANINE 4 MONOOXYGENASE;

AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; COLONOSCOPY; CONTINUOUS INFUSION; DISEASE SPECIFIC SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LOCAL RECURRENCE FREE SURVIVAL; MAJOR CLINICAL STUDY; MALE; METASTASIS FREE SURVIVAL; PERINEURAL INVASION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECTUM CANCER;

AGED; AGED, 80 AND OVER; ASPARTATE-AMMONIA LIGASE; CHEMORADIOTHERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RECTAL NEOPLASMS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84905041599     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-1895-z     Document Type: Article

References (28)

1. Health Promotion Administration, Ministry of Health and Welfare Web site: Available from: https://cris.hpa.gov.tw. Accessed January 1, 2014.
2. Sauer R, Becker H, Hohenberger W, Rödel C, Wittekind C, Fietkau R, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351(17):1731-40.
3. Gérard JP, Conroy T, Bonnetain F, Bouché O, Chapet O, Closon-Dejardin MT, et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol. 2006;24(28):4620-5. (Pubitemid 46630960)
4. Bosset JF, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006;355(11):1114-23. (Pubitemid 44394918)
5. Valentini V, Coco C, Picciocchi A, Morganti AG, Trodella L, Ciabattoni A, et al. Does downstaging predict improved outcome after preoperative chemoradiation for extraperitoneal locally advanced rectal cancer? A long-term analysis of 165 patients. Int J Radiat Oncol Biol Phys. 2002;53(3):664-74. (Pubitemid 34626505)
6. Crane CH, Skibber JM, Feig BW, Vauthey JN, Thames HD, Curley SA, et al. Response to preoperative chemoradiation increases the use of sphincter-preserving surgery in patients with locally advanced low rectal carcinoma. Cancer. 2003;97(2):517-24. (Pubitemid 36133820)
7. Rödel C, Martus P, Papadoupolos T, Füzesi L, Klimpfinger M, Fietkau R, et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol. 2005;23(34):8688-96. (Pubitemid 46211512)
8. Read TE, McNevin MS, Gross EK, Whiteford HM, Lewis JL, Ratkin G, et al. Neoadjuvant therapy for adenocarcinoma of the rectum: tumor response and acute toxicity. Dis Colon Rectum. 2001;44(4):513-22. (Pubitemid 32336425)
9. Tennant DA, Durán RV, Gottlieb E. Targeting metabolic transformation for cancer therapy. Nat Rev Cancer. 2010;10(4):267-77.
10. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-74.
11. Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. Nat Rev Cancer. 2011;11(2):85-95.
12. Huang HY, Wu WR, Wang YH, Wang JW, Fang FM, Tsai JW, et al. ASS1 as a novel tumor suppressor gene in myxofibrosarcomas: aberrant loss via epigenetic DNA methylation confers aggressive phenotypes, negative prognostic impact, and therapeutic relevance. Clin Cancer Res. 2013;19(11):2861-72.
13. Lan J, Tai HC, Lee SW, Chen TJ, Huang HY, Li CF. Deficiency in expression and epigenetic DNA methylation of ASS1 gene in nasopharyngeal carcinoma: negative prognostic impact and therapeutic relevance. Tumour Biol. 2014;35(1):161-9.
14. Richards NG, Kilberg MS. Asparagine synthetase chemotherapy. Annu Rev Biochem. 2006;75:629-54. (Pubitemid 44118046)
15. Kilberg MS, Barbosa-Tessmann IP. Genomic sequences necessary for transcriptional activation by amino acid deprivation of mammalian cells. J Nutr. 2002;132(7):1801-4. (Pubitemid 34742859)
16. Sutow WW, Garcia F, Starling KA, Williams TE, Lane DM, Gehan EA. L-asparaginase therapy in children with advanced leukemia The Southwest cancer chemotherapy study group. Cancer. 1971;28(4):819-24.
17. Jaffe N, Traggis D, Das L, Moloney WC, Hann HW, Kim BS, et al. L-asparaginase in the treatment of neoplastic diseases in children. Cancer Res. 1971;31(7):942-9.
18. Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med. 2006;354(2):166-78. (Pubitemid 43076714)
19. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC cancer staging manual. 7th ed. New York: Springer; 2010.
20. Dworak OKL, Hoffmann A. Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis. 1997;12:19-23. (Pubitemid 27138353)
21. Tian YF, Chen TJ, Lin CY, Chen LT, Lin LC, Hsing CH, et al. SKP2 overexpression is associated with a poor prognosis of rectal cancer treated with chemoradiotherapy and represents a therapeutic target with high potential. Tumour Biol. 2013;34(2):1107-17.
22. Snijders AM, Nowak N, Segraves R, Blackwood S, Brown N, Conroy J, et al. Assembly of microarrays for genome-wide measurement of DNA copy number. Nat Genet. 2001;29(3):263-4. (Pubitemid 33096449)
23. Balasubramanian MN, Butterworth EA, Kilberg MS. Asparagine synthetase: regulation by cell stress and involvement in tumor biology. Am J Physiol Endocrinol Metab. 2013;304(8):E789-99.
24. Zhang B, Dong LW, Tan YX, Zhang J, Pan YF, Yang C, et al. Asparagine synthetase is an independent predictor of surgical survival and a potential therapeutic target in hepatocellular carcinoma. Br J Cancer. 2013;109(1):14-23.
25. Liu RY, Dong Z, Liu J, Zhou L, Huang W, Khoo SK, et al. Overexpression of asparagine synthetase and matrix metalloproteinase 19 confers cisplatin sensitivity in nasopharyngeal carcinoma cells. Mol Cancer Ther. 2013;12(10):2157-66.
26. Appel IM, den Boer ML, Meijerink JP, Veerman AJ, Reniers NC, Pieters R. Up-regulation of asparagine synthetase expression is not linked to the clinical response L-asparaginase in pediatric acute lymphoblastic leukemia. Blood. 2006;107(11):4244-9. (Pubitemid 43801347)
27. Lorenzi PL, Llamas J, Gunsior M, Ozbun L, Reinhold WC, Varma S, et al. Asparagine synthetase is a predictive biomarker of Lasparaginase activity in ovarian cancer cell lines. Mol Cancer Ther. 2008;7(10):3123-8.
28. Dufour E, Gay F, Aguera K, Scoazec JY, Horand F, Lorenzi PL, et al. Pancreatic tumor sensitivity to plasma L-asparagine starvation. Pancreas. 2012;41(6):940-8.